Warrants

Quince Therapeutics announced a securities purchase agreement to raise approximately $11.5 million upfront, with the potential for an additional $10.4 million if warrants are exercised. The financing, priced at a premium, will fund working capital, R&D, and general corporate purposes, extending its operational runway into Q2 2026 (or potentially H2 2026). The placement is led by Nantahala Capital and is set to close in June 2025.

Venus Concept is raising capital through a registered direct offering. The company aims to raise $1.15 million initially by selling common stock at $2.65 per share, with an additional $2.3 million possible through warrants. The offering, which is expected to close around June 9, 2025, will provide funds for general corporate purposes. Venus Concept, a medical aesthetic technology provider in over 60 countries, offers a range of devices and is driven by investors in the healthcare industry.

Helius Medical Technologies has priced its public offering, offering 2,768,600 shares of Class A common stock equivalents with warrants for an additional 2,768,600 shares at $3.27 per unit. Warrants have a 2.5-year lifespan and an initial exercise price of $7.35. The offering is expected to close June 6, 2025, with gross proceeds of $9.1 million. Maxim Group LLC is the placement agent.